Depression among women may pose increased stroke risk, study finds
NEW YORK — It seems that depressed women are at greater risk of having a stroke, a recent study has concluded.
Published online in Stroke: Journal of the American Heart Association, researchers led by Kathryn Rexrode, Brigham and Women’s Hospital associate physician and Harvard Medical School assistant professor of medicine, followed up with 80,574 patients enrolled in the Nurses’ Health Study cohort — a sample of female patients ages 54 to 79 years without a history of stroke from 2000 to 2006 — 22.3% were depressed at baseline, which consisted of patients that currently reported or had a history of any of the three conditions: physician-diagnosed depression, regular use of antidepressant medication or a score of less than or equal to 52 on the five-item Mental Health Index.
During the 6-year period, 1,033 incident strokes were confirmed. Among those stroke patients, 893 did not use antidepressants, compared with 140 patients who reported antidepressant use. The study authors found that patients with a history of depression were at a 29% increased risk of suffering a stroke. Further, patients that were using antidepressants, particularly selective serotonin reuptake inhibitors (also known as SSRIs), had an increased stroke risk of 39%.
Stroke is the third-leading cause of death in the United States, the researchers noted.
Zyprexa,Risperdal and Seroquel health risk. Weight gain, increases in triglyceride levels and associated risks for diabetes and cardiovascular disease. The average weight gain (adults) over the 12 week study period was the highest for Zyprexa—17 pounds. One in 145 adults died in clinical trials of those taking the antipsychotic drugs Zyprexa. This is Lilly's # 1 product over $ 4 billion year sales,moreover Eli Lilly also make billions on drugs that treat the diabetes often that has *been caused* by the Zyprexa! --- Daniel Haszard Zyprexa victim activist and patient who got diabetes from it. http://www.zyprexa-victims.com
Supervalu announces flu shot availability
EDEN PRAIRIE, Minn. — Supervalu on Monday announced that flu vaccination services now are available across all of its pharmacy locations.
Supervalu pharmacies operate in 25 states under 10 retail brands, including Acme Sav-on Pharmacy, Albertsons Sav-on Pharmacy, Albertsons Osco Pharmacy, Cub Pharmacy, Farm Fresh Pharmacy, Jewel-Osco Pharmacy, Shaw’s Osco Pharmacy, Shop ‘n Save Pharmacy, Shop ‘n Save Osco Pharmacy and Shoppers Pharmacy.
Certified pharmacists currently are available to administer the traditional flu vaccine, needle-free FluMist nasal spray and the Fluzone high dose for patients ages 65 years and older during regular pharmacy hours. In addition, some of Supervalu’s stores without pharmacies will host walk-in flu shot clinics.
Shots will not be administered at Save-A-Lot or Hornbacher’s, the company stated.
Flu vaccines are priced at $28.99 for either the traditional shot or FluMist. Fluzone HD is available for $59.99. This cost is covered by Medicare Part B and many commercial health plans, which means many customers may not incur out-of-pocket expenses, Supervalu noted.
No comments found
Study: Investigational GSK, Impax drug reduces Parkinson’s symptoms
HAYWARD, Calif. — Patients taking an experimental treatment for Parkinson’s disease experienced greater reduction in symptoms than those taking a drug already on the market, according to results of a late-stage clinical trial.
GlaxoSmithKline and Impax Pharmaceuticals announced results of the 110-patient phase-3 "ASCEND-PD" trial of IPX066, an extended-release capsule of the Parkinson’s drug carbidopa-levodopa that the companies are comparing with carbidopa-levodopa entacapone, also called CLE. Impax Pharmaceuticals is the branded drugs division of Impax Labs, a generic drug company.
The goal of the study was to reduce "off time," the amount of time during waking hours after a Parkinson’s drug has worn off when symptoms of the disease return, with patients entering the study with a baseline off time of 36.1%, or 5.9 hours. Patients taking IPX066 experienced off time of 24%, or 3.8 hours, compared with 32.5%, or 5.2 hours, among patients taking CLE. This represented a 33.5% reduction in off time for IPX066 patients, versus 10% among CLE patients.
"Impax Pharmaceuticals and GSK are excited to report these positive results for the ASCEND-PD trial, which demonstrate an 84-minute improvement in ‘off time’ over CLE therapy with a corresponding increase in ‘on time’ without troublesome dyskinesia," Impax Pharmaceuticals chief scientific officer Suneel Gupta said.
No comments found